SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Nuvilex, Inc. (OTCQB: NVLX) announced today successful results for the treatment of breast cancer from preclinical studies. In recently completed work using the Nuvilex live-cell encapsulation technology and a combination of two anticancer drugs, clear positive results of elimination of breast tumors were achieved in preclinical models.
